SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001178913-22-000575
Filing Date
2022-02-11
Accepted
2022-02-11 06:01:49
Documents
13
Period of Report
2022-02-11
Items
Item 5.07: Submission of Matters to a Vote of Security Holders

Document Format Files

Seq Description Document Type Size
1 8-K form8k.htm   iXBRL 8-K 37838
  Complete submission text file 0001178913-22-000575.txt   220496

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA cmmb-20220211.xsd EX-101.SCH 4701
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE cmmb-20220211_def.xml EX-101.DEF 18329
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE cmmb-20220211_lab.xml EX-101.LAB 28549
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE cmmb-20220211_pre.xml EX-101.PRE 20565
7 EXTRACTED XBRL INSTANCE DOCUMENT form8k_htm.xml XML 6623
Mailing Address KIRYAT ATIDIM, BUILDING 7 TEL AVIV L3 6158002
Business Address KIRYAT ATIDIM, BUILDING 7 TEL AVIV L3 6158002 972-77-331-0156
Chemomab Therapeutics Ltd. (Filer) CIK: 0001534248 (see all company filings)

IRS No.: 813676773 | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38807 | Film No.: 22616440
SIC: 2834 Pharmaceutical Preparations